Audit: QRS - CLA for Health & Longevity

Audit conducted on 19/09/2026 03:45 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells against ER Therapeutic Protocol, time cells against Practical Considerations and Benefit-Modifying Factors, all 12 monitoring rows against the ER biomarker table, gates against Key Interactions & Contraindications.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	action_3_sub keeps “No trial has compared single with split dosing”; marker_12_target keeps “No established target”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute avoid-populations stay in the STOP gate; monitor/caution interactions stay in the CAUTION gate.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits, risks, contraindications and interactions each map to their own ER section; no modifying factor is promoted to a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names (Tonalin/Clarinol) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Flat, measured register matching the ER’s sceptical framing of CLA.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; cadence and protocol cells are stated as noun phrases.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should”, or “must”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms used are carried over from the ER where no plainer equivalent exists.
2.8	Information is presented in a concise and very compact manner	🟢	Every item is a single condensed phrase or clause.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets and a 12-row monitoring panel address exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, repeat laboratory panels and DXA-grade body-composition tracking assume this willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance sets the marginal benefit against the metabolic cost rather than repeating the marketing claim.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No route-of-administration or adverse-event colloquialisms; at-a-glance wording mirrors the ER Conclusion verbatim.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Byte-identical to [qrs_template] for all fixed headings, gate heads, tier labels and table headers.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variables present; the repeatable marker_#_* and qualitative_item_# spans expanded to 12 and 6 instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans, CSS block, print rules and footer disclaimer are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped to the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose”, “Isomer ratio”, “Split dosing” are the ER’s bold labels verbatim; all 12 monitoring row labels match the ER biomarker table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Where the ER supplies a label it is reused verbatim; the time-to-effect cells derive from a single ER prose bullet that carries no per-aspect labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s ⚠️ Conflicted markers are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is already condensed to the minimum permitted by items 8.2, 9.2, 14.2 and 15.2, which mandate the full population, interaction, biomarker and qualitative lists.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the only element before <html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no duplicate on-page rendering.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: cla_2026-0919-0003_Opus_ER.md (line 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.11 matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0919-0247.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, context-window qualifier correctly excluded.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: cla_2026-0919-0003_Opus_QRS.html matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“CLA for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“CLA for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0919-0247 → “09/19/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all three Conclusion paragraphs: marginal benefit, metabolic cost, dietary-versus-supplement split.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct sentence of the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Only “CLA”, the intervention’s own canonical name, which the first clause immediately defines as “a fat from grazing animals”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Direction only (“falls slightly”, “rises less”); no figures.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the “Populations who should avoid CLA” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 8 ER avoid-populations present, in ER order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationales stripped throughout (e.g., “because milk fat falls measurably at doses as low as 1.5 g/day”, “for whom only a single small trial exists”).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Glycated hemoglobin ≥5.7%, ≥3 of five criteria, waist thresholds, ALT >2× upper limit, Child-Pugh B/C and Lp(a) 50 mg/dL (125 nmol/L) all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses “>” only as a numeric threshold with its unit attached, never as ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated, and the ER does identify such populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the ER’s ten interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 10 interactions present; none duplicates a STOP-gate entry.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every Caution/Monitor verdict, mechanism and mitigation sentence is stripped; only the label and drug list remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All ten named drug/agent lists preserved intact.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER’s interaction parentheticals; all are plain comma-separated drug lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated, and the ER does identify such interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, isomer ratio and split dosing — the only three ER protocol bullets that specify an executable action; the remainder are non-actionable context.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; labels verbatim, values and subs condensed from the matching ER bullet.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Earliest measurable change (~8 weeks), body weight (past 12 weeks) and full accumulation (~6 months) — the three landmarks in the ER’s “Time to effect” bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	All three attach to the ER’s single High-tier benefit (body weight and fat mass), so the ER’s own ordering is preserved.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated from Practical Considerations and Benefit-Modifying Factors.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information; the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight ER benefit headings represented across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of the ER’s own benefit headings; no magnitude, funding note or mechanism carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry at least one ER benefit.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine ER risk headings represented across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of the ER’s own risk headings; no magnitude lines or “Net reading” commentary carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry at least one ER risk.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 12 ER table rows present with matching names and targets: fasting glucose, fasting insulin, HOMA-IR, glycated hemoglobin, LDL, HDL, triglycerides, lipoprotein(a), ALT, AST, hs-CRP, body fat percentage.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Reproduces the ER’s baseline, 4-week, 12-week, 6-month and post-first-year schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER’s “Qualitative markers worth tracking alongside the labs” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 ER qualitative markers present, in ER order.

Issues 19/09/2026 03:45

Pass rate 100.00%. No issues found.

Issues 19/09/2026 03:41

1. 2.15 — Consumer-grade term for cardiovascular: [marker_8_why] (QRS line 715) reads “Rose on 12 months of CLA; independent heart risk”, substituting the lay word “heart” for the clinical term the ER uses in the same table row — “carries independent cardiovascular risk” (ER line 442).

Fixes 19/09/2026 03:41

1. 2.15 — Consumer-grade term for cardiovascular: Changed [marker_8_why] from “independent heart risk” to “independent cardiovascular risk”, matching the clinical term used in the ER’s Monitoring table.

Issues 19/09/2026 03:34

1. 14.3 — Cadence loses first-year anchor: monitoring_cadence (line 764) ends “then every 6–12 months”, but ER line 431 places that interval “After the first year”; as written the sheet reads as if 6–12-monthly retesting begins at the 6-month mark.
2. 15.2 — Hepatic warning loses its scope: qualitative_item_6 (line 799) renders ER line 455 “Any yellowing of the eyes or skin, dark urine, or right-sided abdominal pain” without the leading “Any”, converting a watch-for-any-sign instruction into a flat symptom list.
3. 2.15 — Colloquial “slips” for “deteriorated”: qualitative_item_4 (line 789) writes “if glucose handling slips” where ER line 453 writes “if glucose handling deteriorated”; “slips” is consumer-grade register introduced by the QRS.

Fixes 19/09/2026 03:34

1. 14.3 — Cadence first-year anchor restored: monitoring_cadence now closes “after the first year, every 6–12 months” instead of “then every 6–12 months”, matching the ER’s placement of that interval after the first year of use.
2. 15.2 — Hepatic warning scope restored: qualitative_item_6 changed from “Yellowing of eyes or skin, dark urine, right-sided abdominal pain” to “Any yellowing of eyes or skin, dark urine, or right-sided abdominal pain”, recovering the ER’s watch-for-any-sign framing.
3. 2.15 — Colloquial verb replaced: qualitative_item_4 changed “if glucose handling slips” to “if glucose handling deteriorates”, restoring the ER’s clinical register.

Issues 19/09/2026 03:26

1. 1.1 — Dose qualifier dropped: [action_1_sub] (QRS line 456) says “Most trials used 3.2–4.5 g/day” while ER line 350 says “Most trials showing effects used 3.2–4.5 g/day”, turning a claim about the positive-result subset into one about the whole literature.
2. 1.3 — Hedge removed from waist marker: [qualitative_item_1] (QRS line 773) reads “which shift before the scale”; ER line 450 reads “which often shift before the scale does”, so the hedge “often” was dropped.
3. 2.6 / 2.9 — Imperative addresses the reader: [marker_12_target] (QRS line 748–750) reads “No established target; track own baseline”, a bare imperative whose dangling possessive resolves only as “your own”; the ER (line 446) uses the non-addressing “track change from the individual’s own baseline”.
4. 4.2 / 4.3 — Interaction labels paraphrased: [caution_items] line 600 uses “Additive glucose or lipid supplements” instead of the ER bold label “Supplements with additive glucose or lipid effects” (ER line 313), and line 599 uses “Omega-3 and polyunsaturated oils” instead of “Omega-3 and other polyunsaturated oils” (ER line 311).

Fixes 19/09/2026 03:26

1. 1.1 — Dose qualifier restored: [action_1_sub] changed from “Most trials used 3.2–4.5 g/day” to “Most trials showing effects used 3.2–4.5 g/day”, matching ER line 350.
2. 1.3 — Hedge restored on waist marker: [qualitative_item_1] changed from “which shift before the scale” to “which often shift before the scale”, restoring the ER’s “often”.
3. 2.6 / 2.9 — Reader-addressing imperative removed: [marker_12_target] changed from “No established target; track own baseline” to “No established target; the individual’s own baseline”.
4. 4.2 / 4.3 — Interaction labels restored verbatim: [caution_items] changed “Additive glucose or lipid supplements” to “Supplements with additive glucose or lipid effects” and “Omega-3 and polyunsaturated oils” to “Omega-3 and other polyunsaturated oils”, matching the ER bold labels at lines 313 and 311.

Issues 19/09/2026 03:21

1. 4.5 — Sheet overruns one A4 page: Free-text fields were transcribed from the ER rather than condensed — all 12 marker_#_why cells, all 6 qualitative_item_# entries, the three-line monitoring_cadence (lines 785–789), and the 3–4 line action_1_sub / time_2_sub (lines 455–458, 517–520) — which together with the 18 wrapped gate lines and the 12-row biomarker table pushes the sheet well past the single-page budget.

Fixes 19/09/2026 03:21

1. 4.5 — Condensed sheet to one A4 page: Compressed the verbatim ER transcriptions that caused the overrun — all 12 marker_#_why cells and marker_12_target to single short lines (e.g. “The single marker most reliably moved in the wrong direction by CLA” to “Most reliably moved the wrong way by CLA”), all six qualitative_item_# entries, the three action_#_sub and three time_#_sub cells, and monitoring_cadence (three lines to two). Also trimmed the longest gate parentheticals (waist and Child-Pugh items, three interaction items) without dropping any threshold, severity class, or example drug, leaving all 8 contraindications, 10 interactions, 12 biomarkers, and 6 qualitative markers in place.

Issues 19/09/2026 03:11

1. 1.2 — Split-dosing caution dropped: [action_3_sub] at QRS line 483 carries the ER’s Timing bullet (ER line 356) instead of the Split dosing bullet, so the ER’s explicit caution “No trial has compared single with split dosing” (ER line 354) is absent from a cell labelled “Split dosing”.
2. 11.2 — Time-to-effect cells out of order: The three time cells run “Past 12 weeks” (line 500), “About 6 months” (line 514), “About 8 weeks” (line 528); since all three describe the same body-composition benefit, magnitude cannot order them and the earliest milestone should not sit last.

Fixes 19/09/2026 03:11

1. 1.2 — Split-dosing caution restored: Replaced [action_3_sub], which carried the ER’s Timing bullet, with the ER’s Split dosing bullet text, so the cautious phrasing “No trial has compared single with split dosing” now appears under the “Split dosing” label.
2. 11.2 — Time-to-effect cells reordered: Reordered the three time cells chronologically — “Earliest measurable change / About 8 weeks”, then “Body weight / Past 12 weeks”, then “Full accumulation / About 6 months” — instead of 12 weeks, 6 months, 8 weeks.

Issues 19/09/2026 03:09

1. 1.1 — Time-to-effect label overstates ER: time_1_label (line 497) reads “Body weight & fat mass”, but the ER supports only body weight at the 12-week milestone (“Pooled data show body weight effects emerge past 12 weeks”, ER line 405), and the QRS’s own sub-text on line 504 refers to body weight alone.
2. 4.2 / 4.3 — ER bold label dropped from interaction item: The final Key Interactions item (line 606) reads “A fat-restricted diet, bariatric surgery”; the ER’s bold label is “Other interventions (a fat-restricted diet, bariatric surgery)” (ER line 315), so the label was replaced by its own parenthetical.

Fixes 19/09/2026 03:09

1. 1.1 — Time-to-effect label narrowed to ER claim: Changed time_1_label from “Body weight & fat mass” to “Body weight”, matching the ER’s statement that pooled data place body weight effects past 12 weeks.
2. 4.2 / 4.3 — ER bold label restored on interaction item: Changed the final Key Interactions item from “A fat-restricted diet, bariatric surgery” to “Other interventions (a fat-restricted diet, bariatric surgery)”, restoring the ER’s bold label with its parenthetical preserved.

Issues 19/09/2026 03:04

1. 11.4 — Tautological time-to-effect sub: time_1_sub (lines 503–506) reads “Pooled data show body weight effects emerge past 12 weeks; effects are larger beyond 12 weeks of continuous use”, which restates the 12-week value twice and carries no additional information from the ER.

Fixes 19/09/2026 03:04

1. 11.4 — Tautological time-to-effect sub: Rewrote time_1_sub from “Pooled data show body weight effects emerge past 12 weeks; effects are larger beyond 12 weeks of continuous use” to “Pooled data place the emergence of body weight effects past this point; effects are larger above 3.4 g/day and in participants older than 44”, removing the duplicated 12-week statement and adding the ER’s dose and age modifiers.

Issues 19/09/2026 02:58

1. 1.1 / 11.1 — Fat-free mass time-to-effect unsupported: The third Time-to-Effect cell (lines 523–536) states “Fat-free mass — 7 weeks”, but the ER gives 7 weeks only as the duration of one resistance-training trial (ER line 163), never as a time to effect; it also contradicts the ER’s own “Nothing measurable before about 8 weeks” (ER line 405), which the QRS itself reproduces at line 504.

Fixes 19/09/2026 02:58

1. 1.1 / 11.1 — Fat-free mass time-to-effect unsupported: Replaced the third Time-to-Effect cell “Fat-free mass / 7 weeks” with the ER’s own third time-to-effect statement, “Earliest measurable change / About 8 weeks”, and rewrote time_1_sub to carry the 12-week emergence and dose-duration point so the 8-week fact is no longer duplicated.

Issues 19/09/2026 02:53

1. 1.1 / 11.4 — Time-to-effect value unsupported: [time_1_value] on line 500 reads “8–12 weeks” for “Body weight & fat mass”, but the ER (line 405) states “Nothing measurable before about 8 weeks” and that “body weight effects emerge past 12 weeks”; the headline value contradicts both the ER and its own [time_1_sub] on line 504.

Fixes 19/09/2026 02:53

1. 1.1 / 11.4 — Time-to-effect value unsupported: Changed [time_1_value] from “8–12 weeks” to “Past 12 weeks” so the headline matches the ER’s “body weight effects emerge past 12 weeks” and no longer contradicts its own sub-text.